Product Pipeline
A developer of immunotherapeutics, Corixa is committed to treating and preventing autoimmune disease, cancer and infectious disease by understanding and directing the immune system. Corixa has a broad technology platform that serves as a foundation for fully integrated vaccine design as well as the discovery of component technology for use in other products. We currently have 16 programs in clinical development and 22 programs in preclinical development, including our most advanced product candidate, BEXXAR® therapy.

Corixa partners with numerous developers and marketers of pharmaceuticals and diagnostics, developing products that are Powered by Corixa™ to treat patients worldwide. Corixa was founded in 1994 and is headquartered in Seattle, Washington, with additional operations in Hamilton, Montana, and South San Francisco, California.

BEXXAR, a radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma, has completed certain Phase III clinical trials with additional trials ongoing. BEXXAR is currently being reviewed for approval by the U.S. FDA.

MELACINE® vaccine, a therapeutic melanoma vaccine, is approved in Canada, and we are in discussions with the FDA regarding MELACINE's future regulatory path.

In addition to our late-stage product candidates for cancer, we are also developing MPL® adjuvant, a widely partnered vaccine adjuvant currently being tested with a variety of commercially approved vaccines; and PVAC™ treatment, a clinical stage immunotherapy for psoriasis. In addition to the 16 programs in clinical trials, Corixa is also developing 22 preclinical programs, and numerous discovery efforts that should continue to feed the company's product pipeline for many years to come.

A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.